BIA
CYTK icon

Bell Investment Advisors’s Cytokinetics CYTK Stock Holding History

Bell Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69K Buy
55
+19
+53% +$1.36K ﹤0.01% 1008
2026
Q1 		$2.37K Hold
36
– – ﹤0.01% 1276
2025
Q4 		$2.29K Hold
36
– – ﹤0.01% 1304
2025
Q3 		$1.98K Hold
36
– – ﹤0.01% 1336
2025
Q2 		$1.19K Sell
36
-21
-37% -$730 ﹤0.01% 1536
2025
Q1 		$2.29K Buy
57
+25
+78% +$1.15K ﹤0.01% 1260
2024
Q4 		$1.51K Hold
32
– – ﹤0.01% 1435
2024
Q3 		$1.69K Sell
32
-10
-24% -$557 ﹤0.01% 1418
2024
Q2 		$2.28K Buy
42
+8
+24% +$483 ﹤0.01% 1300
2024
Q1 		$2.38K Hold
34
– – ﹤0.01% 1277
2023
Q4 		$2.84K Buy
+34
New +$1.23K ﹤0.01% 1181
2023
Q3 		– Sell
-31
Closed -$1.01K – 1951
2023
Q2 		$1.01K Hold
31
– – ﹤0.01% 1600
2023
Q1 		$1.09K Buy
31
+19
+158% +$775 ﹤0.01% 1531
2022
Q4 		$550 Buy
+12
New +$516 ﹤0.01% 1771

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's CYTK Position: Q2 2026 in Review

Bell Investment Advisors increased its Cytokinetics (CYTK) stake by 53% in Q2 2026, buying an estimated $1.36K and bringing the position to 55 shares worth $4.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Bell Investment Advisors first reported a position in CYTK in Q4 2022 and has held it in 14 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Bell Investment Advisors held 55 shares of Cytokinetics worth $4.69K as of Q2 2026.
  • Bell Investment Advisors bought 19 Cytokinetics shares in Q2 2026, an estimated $1.36K.
  • Cytokinetics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1008 holding.
  • Bell Investment Advisors first reported a position in Cytokinetics in Q4 2022 and has held it in 14 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.